"10.1371_journal.pone.0090338","plos one","2014-02-27T00:00:00Z","Gareth D Healey; Jennifer A Lockridge; Shawn Zinnen; Julian M Hopkin; Ivan Richards; William Walker","College of Medicine, Swansea University, Swansea, United Kingdom; Allerna Therapeutics Ltd, Swansea University, Swansea, United Kingdom; Lockridge Pharmaceutical Consulting LLC, Westminster, Colorado, United States of America; Zincyte Consulting, Denver, Colorado, United States of America; Sunapten Therapeutics, Kalamazoo, Michigan, United States of America","Conceived and designed the experiments: GDH JAL SZ JMH IR WW. Performed the experiments: GH WW. Analyzed the data: GDH JAL SZ JMH IR WW. Wrote the paper: GDH JAL SZ JMH IR WW.","The authors confirm that funding for this study was from a commercial source (Allerna Therapeutics Ltd), and that during the execution of the study Gareth Healey was an employee of said company. During the execution of this study, Jennifer Lockridge, Shawn Zinnen, Ivan Richards, Julian Hopkin and William Walker acted as consultants to Allerna Therapeutics Ltd. Jennifer Lockridge is the owner of Lockridge Pharmaceutical Consulting, LLC. Shawn Zinnen is the owner of Zincyte Consulting LLC. Ivan Richards is currently (although not at the time of the study) the Chief Executive Officer of Sunapten Therapeutics. The proprietary siRNA used in this study (372) is protected by U.S. patent: U.S.7,566,700 (Materials and Methods for Treatment of Allergic Disease) (Allerna Therapeutics Ltd.). This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","02","Gareth D Healey","GDH",6,TRUE,6,2,6,6,TRUE,TRUE,FALSE,0,NA,FALSE
